|
Showing 1 - 1 of
1 matches in All Departments
Asthma remains a disease with clearly unsatisfactory therapeutics.
With the mounting evidence in support of asthma being an
inflammatory illness, anti-inflammatory agents have now become
prerequisite for the long term management of asthma. Agents such as
2-agonists, antihistaminics, anticholinergics and inhalation
steroids only treat symptoms and do not affect a cure to the
underlying inflammation. On the other hand adenosine receptor
modulators, selective PDE4 inhibitors, leukotriene modifiers and
lipoxygenase inhibitors represent other therapeutic interventions
with more targeted control by acting on different parts of immune
system and the inflammatory processes. A combination of both of
these approaches has been found to improve asthma control with a
reduced dose of steroid. Development of PAF antagonists,
thromboxane inhibitors, IL-4 modulators, antioxidants and anti-IgE
are some of the cutting edge therapies, which offer better hope for
asthma treatment. With many representative agents of each of these
potential therapeutic targets, undergoing clinical studies,
successful development of novel therapeutic agents in this field
are not remote.
|
You may like...
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.